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Alteration in the regulation of the hypothalamic-pituitary-adrenal
(HPA) axis has been implicated in a number of disease states, rang-
ing from metabolic disorders (1) to psychiatric conditions such as
depression (2, 3) and post-traumatic stress disorder (4, 5). Although
the relationship between the different HPA states to the patho-
physiology of these disorders is unclear, reports of the efﬁcacy of
glucocorticoid lowering therapies in metabolic syndrome and in
depression (6–9) suggest a role in pathogenesis and⁄or its mainte-
nance. Clearly, the genetic mechansims that underpin individual
differences in HPA axis function are of considerable importance.
HPA axis output is normally measured in terms of plasma con-
centration of glucocorticoids such as corticosterone (rodent) and
cortisol (human). However, of equal or greater importance is tissue
sensitivity to the steroids. Genetic variations in the two nuclear
receptors for glucocorticoids, mineralocorticoid receptor (MR) and
glucocorticoid receptor (GR), associate with the risk of cardio-meta-
bolic and neuropsychiatric disease (10–13). In addition, the effective
concentration of glucocorticoids within cells can be ampliﬁed by
conversion of inactive steroids, 11-dehydrocorticosterone and corti-
sone, into active glucocorticoids in tissues expressing 11b-hydrox-
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Inter-individual differences in hypothalamic-pituitary-adrenal (HPA) axis activity underlie differ-
ential vulnerability to neuropsychiatric and metabolic disorders, although the basis of this varia-
tion is poorly understood. 11b-Hydroxysteroid dehydrogenase type 1 (11b-HSD1) has previously
been shown to inﬂuence HPA axis activity. 129⁄MF1 mice null for 11b-HSD1 (129⁄MF1
HSD1
)⁄ )) have greatly increased adrenal gland size and altered HPA activity, consistent with
reduced glucocorticoid negative feedback. On this background, concentrations of plasma cortico-
sterone and adrenocorticotrophic hormone (ACTH) were elevated in unstressed mice, and
showed a delayed return to baseline after stress in HSD1-null mice with reduced sensitivity to
exogenous glucocorticoid feedback compared to same-background genetic controls. In the pres-
ent study, we report that the genetic background can dramatically alter this pattern. By contrast
to HSD1
) ⁄) mice on a 129⁄MF1 background, HSD1
)⁄ ) mice congenic on a C57Bl⁄6J back-
ground have normal basal plasma corticosterone and ACTH concentrations and exhibit normal
return to baseline of plasma corticosterone and ACTH concentrations after stress. Furthermore,
in contrast to 129⁄MF1 HSD1
) ⁄) mice, C57Bl⁄6J HSD1
) ⁄) mice have increased glucocorticoid
receptor expression in areas of the brain involved in glucocorticoid negative feedback (hippo-
campus and paraventricular nucleus), suggesting this may be a compensatory response to nor-
malise feedback control of the HPA axis. In support of this hypothesis, C57Bl⁄6J HSD1
)⁄ ) mice
show increased sensitivity to dexamethasone-mediated suppression of peak corticosterone. Thus,
although 11b-HSD1 appears to contribute to regulation of the HPA axis, the genetic background
is crucial in governing the response to (and hence the consequences of) its loss. Similar varia-
tions in plasticity may underpin inter-individual differences in vulnerability to disorders associ-
ated with HPA axis dysregulation. They also indicate that 11b-HSD1 inhibition does not
inevitably activate the HPA axis.
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From Molecular to Translational Neurobiologyysteroid dehydrogenase type 1 (11b-HSD1). In vivo,1 1 b-HSD1 is
the sole enzyme capable of regeneration of active 11-hydroxy ste-
roids from their inactive keto forms (14). 11b-HSD1 is also
expressed in many peripheral sites, including the liver, adipose, and
bone (15, 16). 11ß-HSD1 is also highly expressed in the brain,
including the cortex, hippocampus and cerebellum (17, 18), as well
as the paraventricular nucleus of the hypothalamus (PVN) (19),
where changes in enzyme activity associate with alterations in HPA
axis function (20). The ability of 11b-HSD1 to amplify glucocortic-
oids locally, and its expression in areas known to be relevant to
glucocorticoid regulation of HPA axis control, suggest that the
enzyme may take part in the overall regulation of HPA output, in
addition to modulating local steroid concentrations.
Characterisation of 11b-HSD1 knockout (HSD1
) ⁄ )) mice on a
mixed genetic background (129⁄MF1) showed HPA characteristics
consistent with a role for 11b-HSD1 in HPA regulation. As antici-
pated by the increased clearance of glucocorticoids in these mice
(i.e. the result of the loss of regeneration of steroids by 11b-HSD1
in liver and other peripheral organs), 129⁄MF1 HSD1
) ⁄ ) mice have
enlarged adrenals to compensate (14, 21). However, the null mice
also showed elevated morning (nadir) basal plasma corticosterone
and adrenocorticotrophic hormone (ACTH). Corticosterone rose to
peak levels earlier in the day in 129⁄MF1 HSD1
) ⁄ ) mice (14, 21).
129⁄MF1 HSD1
) ⁄ ) mice also showed an increased early rise in
plasma corticosterone in response to brief restraint (21), and pro-
longed elevation of both ACTH and corticosterone after termination
of restraint (21). Based on these data, and observations of reduced
11b-HSD1 in the hippocampus in obese rats with attenuated HPA
feedback control (22), it was hypothesised that 11b-HSD1 contrib-
utes to glucocorticoid negative-feedback control of the HPA axis
(23). In an effort to further study these initial observations,
MF1⁄129 HSD1
) ⁄ ) mice were repeatedly back crossed onto a
C57Bl⁄6J background to reach genetic homogeneity of background.
On this background, the metabolic and hippocampus-associated
cognitive effects seen on the mixed 129⁄MF1 background are reca-
pitulated (24, 25).
In the present study, we examined the HPA axis in C57Bl⁄6J
HSD1
) ⁄ ) mice and show that basal plasma corticosterone levels in
HSD1
) ⁄ ) mice on the C57Bl⁄6J background, as opposed to that
observed in 129⁄MF1 mice, are similar to controls. To investigate a
mechanism by which this apparent strain difference may be
explained, we determined GR, MR and corticotrophin-releasing fac-
tor (CRF) mRNAs in the brain and performed a dexamethasone sup-
pression test to determine GR-mediated feedback sensitivity.
Materials and methods
Animals
Adult C57Bl⁄6J HSD1
) ⁄ ) male mice were generated by back-crossing a
minimum of 10 generations onto a C57Bl⁄6J (Harlan, Essex, UK) background
from the original MF1⁄129 HSD1
) ⁄ ) line (14). Controls were male C57Bl⁄6J
mice from the same source, maintained and bred within the animal house
designated C57Bl⁄6J HSD1
+ ⁄ +. Animals were housed singly for at least
1 week prior to experiments and were age-matched (between 3–6 months
of age). The light⁄dark cycle was 12 : 12 h (lights on 07.00 h). Animals were
given standard chow and water ad lib, and all studies were carried out
to the highest standards under the aegis of the United Kingdom Animals
Scientiﬁc Procedures Act, 1986. Previously reported data from HSD1
) ⁄ )
male mice on other backgrounds comprised: 129 mice (26) and 129⁄MF1
mice (14, 21).
Circadian measurements
To determine activity of the HPA axis at various times during the circadian
cycle, C57Bl⁄6J HSD1
) ⁄ ) and HSD1
+ ⁄ + mice were sacriﬁced without prior
disturbance at 07.00 h, 13.00 h and 19.00 h. Sacriﬁce was performed by
direct decapitation, and trunk blood was collected into EDTA-coated micro-
vette tubes (Sarstedt, Numbrecht, Germany). Tubes were put on ice until
all samples were collected. Tubes were then spun 10 min at 2300 g in a
chilled microcentrifuge. Supernatants (plasma) were stored at )20  C until
analysed.
Restraint stress
All procedures were carried out between 08.00–10.00 h. C57Bl⁄6J HSD1
) ⁄ )
and HSD1
+ ⁄ + mice were removed from their home cage to a nearby proce-
dure room. Restraint was carried out for 10 min by placing the mouse into
a 50 ml Falcon tube (Greiner Bio-One, Gloucestershire, UK), which was mod-
iﬁed to allow the tail to protrude out the back with a breathing hole at the
front. Mice were either sacriﬁced immediately or returned to their home
cage. Separate groups of mice were sacriﬁced 10, 45 or 90 min after the
start of restraint. An additional group of mice was sacriﬁced without expo-
sure to restraint within 1 min after removal from their home cage to obtain
basal corticosterone levels. Killing and blood collection were performed as
above.
Analysis of plasma hormones
Analysis of plasma corticosterone and ACTH was performed as described
previously (21). In short, corticosterone was measured by radioimmunoassay
using
3H -corticosterone label, and a polyclonal anti-corticosterone antibody
(kind gift of Dr C. J. Kenyon, Edinburgh). ACTH was measured by an
enzyme-linked immunosorbent assay kit using a monoclonal anti-human
ACTH antibody designed against regions of ACTH that are 100% conserved
in the mouse (Biomerca, Newport Beach, CA, USA).
Adrenal measurements
Left adrenals were removed at sacriﬁce from C57Bl⁄6J HSD1
) ⁄ ) and
HSD1
+ ⁄ + mice, and placed immediately into 4% paraformaldehyde (Sigma-
Aldritch, Poole, UK). Twenty-four hours post ﬁxation, adrenals were cleaned
of any attached fat by manual dissection. Adrenals were then weighed on a
microbalance. Body weight of mice was taken prior to sacriﬁce.
In situ hybridisation
In situ hybridisation was performed as described previously (21). All in situ
experiments were performed on fresh frozen brains collected after decapita-
tion from unstressed animals at the nadir of the corticosterone rhythm
(08.00 h). Cryostat cut sections (10 lm) were collected at the level of the
hypothalamic paraventricular nucleus and the dorsal hippocampus. CRF, GR
and MR mRNAs were all detected by riboprobe based in situ hybridisation
autoradiography. Brieﬂy, plasmids containing fragments of cDNA for rat GR
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CRF (518 bp; PvuII-BamHI fragment) were used as templates to transcribe
35S-UTP radiolabelled antisense riboprobes. After hybridisation and stringent
washes, the sections were exposed to autoradiographic ﬁlm (XAR-5; Kodak,
Kemel Hempstead, UK). Speciﬁc optical density measurements of different
regions of the brain were obtained after subtraction of background density
(obtained over white matter), average from eight to ten measurements⁄area
per section, three sections per anatomical area⁄mouse using computer-dri-
ven densitometry (MCID; Interfocus, Cambridge, UK). CRF was measured
exclusively in the PVN, MR in the dorsal hippocampus (CA1, CA3 and den-
tate gyrus), and GR was measured in the PVN and the three divisions of the
dorsal hippocampus.
Preparation of RNA from pituitaries
Pituitaries were obtained from freshly killed mice, and immediately frozen
on dry ice. RNA was obtained from each single pituitary by homogenisa-
tion in 300 ll Trizol reagent (Gibco BRL, Paisley, UK) on ice (4  C) using a
hand held glass homogeniser. Homogenates were transferred to a 1.5-ml
eppendorf and incubated at room temperature for 5 min. To each, 30 ll
of chloroform was added, contents mixed by inversion, and then spun at
4  C at 9300 g for 10 min in a table top microcentrifuge. The top layer
containing RNA was removed, and transferred to a new eppendorf tube.
One volume of 70% ethanol was added, contents mixed, and RNA puriﬁed
using the RNeasy puriﬁcation kit (Qiagen, GmbH, Hilden, Germany).
Samples were transferred to an RNEasy column and spun for 15 s at
15 700 g at room temperature. Seven hundred microlitres of buffer RW1
was added to the column, and the column was spun for another 15 s at
15 700 g. Five hundred microlitres of buffer RPE was added and spun for
15 s at 15 700 g Another 500 ll of buffer RPE was added and spun for
2 min at 15 700 g. The column was spun once more (dry) for 1 min at
15 700 g to remove trace wash solution. Column bound RNA was eluted
from the column by adding 30 ll RNAse free water followed by a spin
for 1 min at 15 700 g. RNA was stored at )80  C until ready for cDNA
synthesis.
cDNA synthesis from pituitary RNA
cDNA from pituitary RNA was synthesised using Invitrogen cDNA synthesis
reagents (Invitrogen, Carlsbad, CA, USA). Approximately 0.5 lg of RNA was
heated to 70  C for 10 min then placed on ice. RNA was incubated in a
20-ll reaction containing 1st-Strand reaction buffer, 500 lM dNTPs, 2.5 mM
MgCl2,5m M dithiothreitol, RNAse inhibitor, 300 ng random primers, and
Superscript III reverse transcriptase. The mixture was incubated at 25  C for
5 min, followed by 60 min at 50  C. The reaction was terminated by incuba-
tion at 80  C for 15 min. cDNA was stored at )20  C until ready for use in
a real-time polymerase chain reaction (PCR) assay. A reaction, which
excluded the Superscript III reverse transcriptase, was performed for each
sample, as a negative control for the real-time PCR reaction.
Quantitative real-time PCR for quantiﬁcation of GR mRNA
Real-time PCR was performed using the Light Cycler 480 PCR machine
(Roche Diagnostics, Mannheim, Germany). Polymerase, buffer and dNTPs
were provided using reagents from the Light Cycler 480 Probes Master kit
(Roche Diagnostics). GR speciﬁc primers⁄probe were designed from mouse
cDNA sequence data and synthesised by Eurogentec S. A. (Seraing, Belgium).
Forward primer: 5¢-CCC TGG AAT GAG ACC AGA TG-3¢, Reverse primer:
5¢-GGT AAT TGT GCT GTT CTT CCA C-3¢, Probe: 5¢-CTG CCT GGT GTG CTC
CGA TGA AGC-3¢. The probe for GR is labelled with the 5¢ﬂuorescence repor-
ter Yakima Yellow, the 3¢ quencher BHQ-1, and detected on the VIC channel
of the Cycler. Quantiﬁcation of GR was expressed relative to an internal
control, 18S. A standard 18S speciﬁc primers⁄probe mix was used (18S Taq-
man gene expresion assay, Hs99999901_s1; Applied Biosystems, Foster City,
CA, USA). The 18S probe was detected on the FAM channel. Primers were
used at a 6 pmol⁄reaction, and probes at 2 pmol⁄reaction. Relative values
of both GR and 18S were calculated by comparison with a standard curve.
Samples to be used to generate standard curves were prepared: 2 llo f
pituitary cDNA from each individual animal was mixed together. This mix-
ture was then serially diluted with PCR grade water to produce standards
with relative concentrations of 1 (The original mixture), 1 : 2, 1 : 4, 1 : 8,
1 : 16, 1 : 32, 1 : 64, 1 : 128 and 1 : 256. Individual pituitary cDNA samples
and their corresponding negative control samples (Superscript III reverse
transcriptase excluded), were diluted 1 : 20 in PCR grade water. Two microli-
tres of 1 : 20 diluted cDNA was mixed with 5 ll master mix, 0.5 ll pri-
mer⁄probe mix and 2.5 llH 2O. Reactions were performed in triplicate for
GR and 18S on the Cycler. PCR was performed using cycling parameters of
50  C for 2 min, 95  C for 10 min, 40 cycles of 95  C for 15 s, and 60  C
for 1 min. Relative cDNA quantities for both GR and 18S were derived from
each reaction by comparison with the standard curve using the absolute
quantiﬁcation⁄second derivative max calculation method on the Light Cycler
480 System. Ampliﬁcation of negative control samples occurred after many
more cycles (> 10) than for experimental samples and were excluded from
the analysis. GR⁄18S ratios were obtained for each individual, and these
ratios were used for presentation and statistical analysis of the data.
Dexamethasone suppression test
To assess dexamethasone feedback regulation of HPA activity, we performed
a modiﬁed version of the dexamethasone suppression test. Mice of both
genotypes were injected i.p. with 200 ll of vehicle [2% ethanol (BDH, Dor-
set, UK)⁄0.9% saline (Sigma-Aldritch)] at 13.00 h. Venesection of the tail
was used to obtain blood samples from these animals at 19.00 h the same
day (near peak of circadian rise in plasma corticosterone). Blood was col-
lected and plasma prepared as above, and processed for corticosterone mea-
surements. At 2-weekly intervals, the same mice were injected with 2 lg⁄kg
or 10 lg⁄kg dexamethasone (Sigma-Aldritch) in approximately 200 ll vehi-
cle at 13.00 h, followed by tail blood sampling at 19.00 h.
Statistical analysis
Adrenal weight, and gene expression data obtained from unstressed animals
were analysed by an independent samples t-test to determine an effect of
genotype. Plasma corticosterone and ACTH data from stress experiments
were analysed by two-way analysis of variance (ANOVA) for the effects of
time and genotype. Corticosterone data from dexamethasone suppression
tests were analysed by a repeated measures design two-way ANOVA. Post-hoc
analysis was performed using the Tukey’s honestly signiﬁcant difference test.
P < 0.05 was considered statistically signiﬁcant.
Results
Adrenal weight is increased in C57Bl⁄6J HSD1
)⁄) mice
Adrenal mass was signiﬁcantly higher in C57Bl⁄6J HSD1
) ⁄ ) mice
compared to control C57Bl⁄6J HSD1
+ ⁄ + mice, by approximately
20% (Fig.1A) (t = 2.19, P = 0.042; n = 10 per group). The adrenal
enlargement was also observed when adrenal weights were
expressed relative to body weight (Fig. 1B) (t = 3.12, P = 0.006;
n = 10), reiterating the ﬁndings on the 129⁄MF1 background (26).
Strain-dependent HPA changes in HSD1
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background (HSD1
+ ⁄ + 38.8 +⁄) 1.5 g, HSD1
) ⁄ ) 35.4 +⁄) 0.73 g;
n = 10).
Circadian rhythms of plasma corticosterone and ACTH
are unaltered in C57Bl⁄6J HSD1
)⁄
) mice
We have previously shown that MF1⁄129 HSD1
) ⁄ ) mice have ele-
vated nadir (08.00 h) and an earlier diurnal rise in plasma cortico-
sterone levels compared to MF1⁄129 HSD1
+ ⁄ + mice. We therefore
investigated the circadian proﬁle of plasma corticosterone in both
C57Bl⁄6J HSD1
) ⁄ ) and C57Bl⁄6J HSD1
+ ⁄ + mice.
Although there was a clear difference between basal levels
(07.00 h) and peak levels (19.00 h) in all mice, two-way ANOVA for
the effects of time and genotype indicated an effect of time
(F2,24 = 9.55, P = 0.001), but not genotype (F1,24 = 1.77, P = 0.196),
nor any interaction between genotype and time (F2,24 = 0.637,
P = 0.537) (Fig. 2A). Therefore, there is no evidence of either
increased basal plasma corticosterone or earlier rise to peak levels
in C57Bl⁄6J HSD1
) ⁄ ) mice. Similarly, plasma levels of ACTH did not
differ between C57Bl⁄6J HSD1
) ⁄ ) and C57Bl⁄6J HSD1
+ ⁄ + mice
(two-way ANOVA). There was no indication of elevated nadir ACTH in
C57Bl⁄6J HSD1
) ⁄ ) mice compared to C57Bl⁄6J HSD1
+ ⁄ + mice
(Fig. 2B), contrasting with ﬁndings previously observed in MF1⁄129
HSD1
) ⁄ ) mice (21).
Altered plasma corticosterone, but not ACTH, response
to restraint stress in C57Bl⁄6J HSD1
)⁄) mice
We have previously shown that MF1⁄129 HSD1
) ⁄ ) mice have an
exaggerated stress-induced rise in plasma corticosterone levels, and
a retarded return to baseline of both corticosterone and ACTH com-
pared to strain controls. In the present study, we determined stress
induced levels of plasma corticosterone in C57Bl⁄6J HSD1
) ⁄ ) and
C57Bl⁄6J HSD1
+ ⁄ + mice.
Again, basal (nadir) plasma corticosterone levels did not differ
between C57Bl⁄6J HSD1
+ ⁄ + and C57Bl⁄6J HSD1
) ⁄ ) mice (Fig. 3A).
Ten minutes of restraint led to marked elevations in plasma cortico-
sterone in mice of both genotypes, but a signiﬁcantly greater
response in C57Bl⁄6J HSD1
) ⁄ ) mice (P < 0.05) (Fig. 3A). These
levels remained elevated over basal after 45 min, but there was a
signiﬁcant reduction of peak values only in the C57Bl⁄6J HSD1
) ⁄ )
mice at this time-point (P < 0.05) (Fig. 3A). By 90 min, plasma
corticosterone levels in both genotypes were similar to unstressed
values (Fig. 3A).
Plasma ACTH levels did not differ between C57Bl⁄6J HSD1
+ ⁄ + and
C57Bl⁄6J HSD1
) ⁄ ) mice, prior to or during the response to restraint
(Fig. 3B). Ten minutes of restraint led to increased levels of plasma
ACTH in mice of both genotypes, returning to baseline by 45 min
(Fig. 3B). A two-way ANOVA for the effect of time and genotype
on plasma ACTH revealed no main effect of genotype
(F6,40 = 0.034, P = 0.85), but a signiﬁcant effect of time (F6,40 =
207.9, P < 0.001).
The normal return to baseline of plasma corticosterone and ACTH
levels in response to restraint stress in C57Bl⁄6J HSD1
) ⁄ ) mice is
indicative of a tightly regulated HPA axis, suggesting that these
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Fig. 1. Adrenal glands are larger in adult male C57Bl⁄6J 11bHSD1
) ⁄ ) mice
compared to C57Bl⁄6J controls. (A) Absolute left side adrenal weights (mg)
are larger in C57Bl⁄6J 11bHSD1
) ⁄ ) mice (*P < 0.05, compared to controls).
(B) Left adrenal weight relative to body weight expressed in mg⁄kg are lar-
ger in C57Bl⁄6J 11bHSD1
) ⁄ ) mice (*P < 0.05, compared to controls). Values
are the mean  SEM.
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Fig. 2. Circadian proﬁle of hypothalamic-pituitary-adrenal axis activity is
normal in adult male C57Bl⁄6J 11bHSD1
) ⁄ ) mice compared to C57Bl⁄6J
control mice. (A) Plasma levels of corticosterone (nM) secreted at 07.00,
13.00 and 19.00 h. Levels at 19.00 h were elevated from basal levels at
06.00 h in both genotypes. There were no differences between genotypes at
any time point. (B) Plasma levels of adrenocorticotrophic hormone (ACTH)
(pg⁄ml) secreted at 07.00, 13.00 and 19.00 h. There were no differences
between genotypes at any time point, nor was there signiﬁcant variation
throughout the day. Values are the mean  SEM.
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HSD1
) ⁄ ) mice. We therefore looked at expression of genes impor-
tant in HPA axis regulation.
C57Bl⁄6J HSD1
)⁄) null mice have altered gene expression
in the paraventricular nucleus of the hypothalamus
and the hippocampus
C57Bl⁄6J HSD1
) ⁄ ) mice show considerable differences in the
expression of HPA relevant genes in the PVN and hippocampus rel-
ative to C57Bl⁄6J HSD1
+ ⁄ + mice. In the PVN, GR mRNA expression
was signiﬁcantly elevated (P < 0.001) and CRF mRNA showed a
tendency to be elevated (P = 0.057) in C57Bl⁄6J HSD1
) ⁄ ) mice
(Fig. 4A). Expression of GR mRNA in the hippocampus was also ele-
vated in C57Bl⁄6J HSD1
) ⁄ ) mice throughout all measured subﬁelds
(P < 0.001) (Fig. 4B). MR mRNA expression was signiﬁcantly ele-
vated only in the CA1 region (P < 0.05), but not in the CA3 and
dentate gyrus in C57Bl⁄6J HSD1
) ⁄ ) mice (Fig. 4C). By contrast, the
expression of GR mRNA in the pituitary was not altered in
C57Bl⁄6J HSD1
) ⁄ ) mice relative to C57Bl⁄6J HSD1
+ ⁄ + mice
(Table 1). The up-regulation of corticosteroid receptors in areas of
the brain (but not pituitary) involved in negative-feedback regula-
tion of the HPA axis suggests that this may be an important mech-
anism whereby C57Bl⁄6J HSD1
) ⁄ ) mice may be able to reset their
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Fig. 3. Initial rise in hypothalamic-pituitary-adrenal axis activity in response
to 10-min restraint is increased in C57Bl⁄6J 11bHSD1
) ⁄ ) mice, but return
to baseline after termination of restraint is normal, compared to C57Bl⁄6J
control mice. (A) C57Bl⁄6J 11bHSD1
) ⁄ ) mice had higher plasma corticoste-
rone levels than C57Bl⁄6J control mice after 10 min of restraint (*P < 0.05
compared to C57Bl⁄6J controls). Corticosterone levels after 45 min were
reduced in C57Bl⁄6J 11bHSD1
) ⁄ ) mice (but not C57Bl⁄6J controls) from
levels observed after 10 min (#P < 0.05 compared to the 10-min time
point). Corticosterone had reached levels indistinguishable from baseline
after 90 min in mice from both genotypes. (B) Plasma adrenocorticotrophic
hormone (ACTH) levels were elevated after 10 min of restraint and had
returned to levels similar to baseline after 45 or 90 min. There were no dif-
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Fig. 4. Basal (nadir) steady-state mRNA levels of corticotrophin-releasing
factor (CRF), glucocorticoid receptor (GR) and mineralocorticoid receptor
(MR) in HSD1
) ⁄ ) and C57Bl⁄6J mice in the paraventricular nucleus (PVN)
and hippocampus. In situ hybridisation for each study was analysed by inte-
grated optical density (IOD) measurements of autoradiographs. (A) IOD mea-
surements for CRF and GR mRNA in the PVN. CRF expression tends towards
being increased in the PVN of HSD1
) ⁄ ) mice (a, P = 0.057, compared to
C57Bl⁄6J controls). GR expression is increased in the PVN of HSD1
) ⁄ ) mice
(*P < 0.05, compared to C57Bl6 controls). (B) IOD measurements for GR
mRNA in the dentate gyrus (DG), CA1 and CA3 areas of the hippocampus.
GR expression is increased in all areas of the hippocampus of HSD1
) ⁄ )
mice (*P < 0.05, compared to C57Bl6 controls). (C) IOD measurements for
MR mRNA in the DG, CA1, and CA3 areas of the hippocampus. MR expres-
sion is increased only in the CA1 of the hippocampus of HSD1
) ⁄ ) mice
(*P < 0.05, compared to C57Bl⁄6J controls). Values are the mean  SEM.
Table 1. Glucocorticoid Receptor (GR) mRNA Expression in the Pituitary of
HSD1
) ⁄ ) and HSD1
+ ⁄ + Mice Estimated by Quantitative Real-Time Polymerase
Chain Reaction (Relative to 18S Internal Control).
Genotype GR⁄18S ratio (mean  SEM)
HSD1
+ ⁄ + 0.998  0.071
HSD1
) ⁄ ) 0.904  0.086
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fore, we determined whether the C57Bl⁄6J HSD1
) ⁄ ) mice have
increased sensitivity to feedback, using the dexamethasone suppres-
sion test.
C57Bl⁄6J HSD1
)⁄) mice show greater sensitivity to
dexamethasone suppression of peak plasma corticosterone
Evening plasma corticosterone levels were suppressed by prior
dexamethasone administration, but the minimal effective dose dif-
fered between C57Bl⁄6J HSD1
) ⁄ ) mice and C57Bl⁄6J HSD1
+ ⁄ +
mice (Fig. 5). Repeated measures ANOVA for between-subjects effect
of genotype and within-subjects effect of dose revealed a main
effect of dose (F = 20.2, P < 0.0001) but not genotype. Post-hoc
analysis revealed that afternoon plasma corticosterone was reduced
from levels observed in vehicle-injected mice with a dose of
2 lg⁄kg dexamethasone in C57Bl⁄6J HSD1
) ⁄ ) mice, but not
C57Bl⁄6J HSD1
+ ⁄ + mice (Fig. 5). Plasma corticosterone was reduced
from levels observed in vehicle-injected mice after a dose of
10 lg⁄kg dexamethasone in mice of both genotypes (Fig. 5). Hence,
C57Bl⁄6J HSD1
) ⁄ ) mice appear to be more sensitive to negative-
feedback signals than controls.
Summary of HPA proﬁle of HSD1
)⁄) mice on different
strain backgrounds
In addition to the data presented for HSD1
) ⁄ ) mice congenic to
C57Bl⁄6J, Table 2 presents a summary of various aspects of the
HPA axis that we found in HSD1
) ⁄ ) mice on a number of different
strain backgrounds. These include our published data on the origi-
nal 129⁄MF1 cross (21) and on HSD1
) ⁄ ) congenic on the 129
background (26).
Adrenal size is increased in HSD1
) ⁄ ) mice on all strain back-
grounds. Consistent with this, early peak stress corticosterone levels
are also increased in HSD1
) ⁄ ) mice on all backgrounds. However,
although basal (early morning) corticosterone levels are increased
in HSD1
) ⁄ ) mice on the 129 and 129⁄MF1, they are the same as
controls on the C57Bl⁄6J background, despite an increased adrenal
size. A disturbed overall rhythm is observed in 129⁄MF1 HSD1
) ⁄ )
but not C57Bl⁄6J HSD1
) ⁄ ) mice. These data suggest that genetic
elements, probably from the 129 strain, contribute to the altered
basal plasma corticosterone of HSD1
) ⁄ ) mice. Shut off of HPA
activity after stress is also abnormal in 129⁄MF1 HSD1
) ⁄ ) mice,
but not in C57Bl⁄6J HSD1
) ⁄ ) mice. In line with these observations
are the ﬁndings regarding GR and MR expression in the brain of
HSD1
) ⁄ ) mice. 129⁄MF1 mice, with features consistent with
impaired negative-feedback regulation of plasma glucocorticoid lev-
els, have reduced GR expression in the PVN. Conversely, C57Bl⁄6J
HSD1
) ⁄ ) mice, with apparent normal plasma glucocorticoid regula-
tion (despite loss of 11b-HSD1), have elevated GR expression in
both the PVN and the hippocampus. Increased suppression by dexa-
methasone of HPA activity in HSD1
) ⁄ ) mice congenic to C57Bl⁄6J
suggests that feedback sensitivity is increased, as would be pre-
dicted from increased GR expression in feedback-sensitive sites
such as the PVN and hippocampus.
Discussion
HPA phenotype of HSD1
)⁄) mice is dependent upon strain
background
In the present study, we report that, on a strain background con-
genic to C57Bl⁄6J, no differences were observed between HSD1
) ⁄ )
mice and HSD1
+ ⁄ + mice in either plasma corticosterone or ACTH
at the nadir of the HPA rhythm. This is in contrast to the marked
hypercorticosteronemia and elevated morning ACTH previously
HSD1+/+
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Fig. 5. C57Bl⁄6J 11bHSD1
) ⁄ ) mice are hypersensitive to dexamethasone
suppression of evening plasma corticosterone compared with C57Bl⁄6J con-
trol mice. C57Bl⁄6J 11bHSD1
) ⁄ ) mice, but not C57Bl⁄6J controls had
reduced evening (19.00 h) plasma corticosterone after 2 lg⁄kg dexametha-
sone given i.p. 5 h previously (*P < 0.05, compared to vehicle). Plasma corti-
costerone was reduced in mice from both genotypes after 10 lg⁄kg
dexamethasone. Values are the mean  SEM.
Table 2. Summary of Hypothalamic-Pituitary-Adrenal Axis Phenotype of
HSD1
) ⁄ ) Mice, From Different Strain Backgrounds.
Measure 129 129⁄MF1 C57Bl⁄6J
Adrenal size ›› ›
Basal AM Cort ›› M
Basal PM Cort ND MM
Peak Stress Cort ND ››
Recovery Cort ND › M
Basal AM ACTH ND › M
Basal PM ACTH ND MM
Peak Stress ACTH ND MM
Recovery ACTH ND › M
CRF mRNA (paraventricular nucleus) ND ﬂ* ›*
GR mRNA (paraventricular nucleus) ND ﬂ›
GR mRNA (hippocampus) ﬂ M ›
MR mRNA (hippocampus) ND M ›*
Arrows designate direction of change in HSD1
) ⁄ ) mice relative to HSD1
+ ⁄ +
mice from the same background: ›, higher; ﬂ, lower; M, not different. All
changes are signiﬁcant to P < 0.05, except those designated by an asterisk
(*), which tend towards change with P < 0.1. Measurements not carried out
on a particular background are indicated by ND (not done). ACTH, adreno-
corticotrophic hormone; CRF, corticotrophin-releasing factor; AM Cort,
morning corticosterone; PM Cort, afternoon corticosterone; GR, glucocorti-
coid receptor; MR, mineralocorticoid receptor.
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) ⁄ ) mice on the MF1⁄129 background (21).
Although adrenal weight was found to be increased in size in
C57Bl⁄6J HSD1
) ⁄ ) mice in the present study, in line with the pre-
vious report, the extent of size difference is much less dramatic.
Adrenal weights were increased approximately 70% in HSD1
) ⁄ )
mice on the MF1⁄129 background (14), but only 20% in C57Bl⁄6J
HSD1
) ⁄ ) mice in the present study. The ability to ‘turn off’ the
hormone response to a stressor is, in part, indicative of the
strength of the negative-feedback signal within the brain and the
anterior pituitary (27). The delayed return of both plasma cortico-
sterone and ACTH to pre-stress levels after restraint, as seen on
MF1⁄129 HSD1
) ⁄ ) mice, is no longer observed in C57Bl⁄6J
HSD1
) ⁄ ) mice. These strain differences in HPA axis parameters
contrast with the similar metabolic and cognitive phenotypes seen
with HSD1
) ⁄ ) on 129⁄MF1 crossed and congenic 129 and
C57Bl⁄6J backgrounds (14, 23, 26, 28, 29).
The phenotype of elevated basal plasma corticosterone is most
likely contributed to largely by genetic modiﬁers within the 129
strain genome. Consistent with this hypothesis is the observation
that the HPA phenotype in HSD1
) ⁄ ) mice on a pure 129 background
is remarkably similar to the phenotype on the MF1⁄129 background,
yet 11b-HSD1
) ⁄ ) mice on a pure MF1 background show little or no
HPA phenotype at all (R. Carter, M. C. Holmes, unpublished
observations), including a lack of both increased adrenal size or peak
corticosterone in response to stress. The 129 strain has often been
compared to other strains, including C57Bl⁄6J, and is known to show
more anxiety-related behaviours in the elevated plus-maze (30), open
ﬁeld (31) and light⁄dark test (32). One hundred twenty-nine mice
also showed greater sensitivity to benzodiazepine anxiolytics (33),
perhaps indicating an altered GABA system. There is some suggestion
of elevated basal corticosterone in 129 relative to C57Bl⁄6J mice
(34), although we found no evidence for this in our own comparisons
(25, 26, 35). However, the importance of genetic background
in determining the phenotype of transgenic animals has been
recognised for some time (36–38). For example, knockout mice for
the ACTH processing genes, prohormone convertase and 7B2 have
phenotypes leading to elevated corticosterone, which is only
observed on a 129, but not C57Bl⁄6J background (34).
Mechanism of resetting of HPA axis feedback in C57Bl6
mice
The phenotype of HSD1
) ⁄ ) mice originally described on the MF1⁄129
background, interpreted as reduced feedback sensitivity, is not
surprising given the expression of HSD1 in feedback-related areas of
the brain (19). The loss of local production of corticosterone would
predict that higher plasma levels of hormone are required to reach
equivalent tissue levels in feedback sites that normally express the
enzyme. It is therefore of interest to speculate how C57Bl⁄6J
HSD1
) ⁄ ) mice maintain apparently normal HPA regulation. The
elevation of GR expression in the hippocampus and PVN may well
compensate for the lack of local cellular corticosterone regeneration.
Indeed, the dexamethasone suppression test provides direct evidence
for increased GR function because C57Bl⁄6J HSD1
) ⁄ ) mice suppress
evening corticosterone levels at a lower dose of dexamethasone than
controls. This squares with the phenotype of transgenic mice with
increased central nervous system (CNS) GR expression, which show
suppressed basal HPA activity (39). Moreover, brain speciﬁc reduction
of GR increases basal HPA activity (40), and global reduction of GR
leads to prolonged HPA activity after restraint (41). Thus, the relative
changes in central GR (increased in C57Bl⁄6J HSD1
) ⁄ ) mice, and
decreased in 129 or MF1⁄129 HSD1
) ⁄ ) mice) correspond well with
their phenotypes of relative high and low feedback, respectively.
These differences suggest that the principle difference between
strains may lie in the regulation of central GR expression. Indeed,
similar HPA axis differences were observed when deletion of the
neurokinin 1 receptor was investigated on a mixed 129⁄C57Bl⁄6
background compared to pure C57Bl⁄6, and, again, a strain
dependent GR up-regulation was considered to underpin these
changes (42). The mechanism by which elevated GR may occur in one
strain, but not another, in response to ablation of HSD1 is unclear.
Intriguingly, the GR gene uses a series of alternate promoters, several
of which are CNS-enriched, and regulated by distinct transcription
factors (43), so possibly this may underlie strain differences in the
response to loss of 11b-HSD1. To elucidate the mechanisms underly-
ing strain speciﬁc GR changes in response to a gene deletion,
mapping of genetic modiﬁers using informative crosses of the
relevant strains would need to be carried out. It is worth noting that
GR was unchanged in the pituitary of C57Bl⁄6J HSD1
) ⁄ ) mice
relative to controls. A body of evidence indicates that the pituitary
gland is an important site of action for glucocorticoid negative
feedback (27, 44, 45). A lack of GR up-regulation in the pituitary in
the C57Bl⁄6J HSD1
) ⁄ ) mice strengthens our view that, in these
experiments, feedback sensitivity is altered by GR changes in the brain
itself. Hence, the correlation of GR mRNA up-regulation and
increased glucocorticoid sensitivity is indicative of increased GR
protein being expressed in the PVN and hippocampus, which
comprise key sites of negative-feedback regulation of the HPA axis.
The results obtained in the present stusy, together with those
from our previous reports (14, 21), suggest that 11b-HSD1 has a
signiﬁcant role in regulating the HPA axis. However, the manner of
adaptation to the loss of 11b-HSD1 in genetically modiﬁed mice
appears to be dependent upon other, probably genetic modiﬁers. The
two phenotypes described on the C57Bl⁄6J and 129⁄MF1 back-
grounds (i.e. either reduced or increased glucocorticoid receptor
functioning) are potentially neuroendocrine markers of psychopa-
thology. For example, melancholic depression is most commonly
associated with elevated basal plasma glucocorticoids and impaired
glucocorticoid receptor functioning (46, 47). By contrast, disorders
such as post-traumatic stress disorder and atypical depression are
associated with low or normal plasma steroids and increased gluco-
corticoid receptor functioning (46, 48). 11b-HSD1, therefore, may be
an important factor in the overall regulation of the HPA axis in this
clinical context, and may itself be relevant to disease susceptibility,
severity or outcome. Furthermore, genetic modiﬁers of HPA adapta-
tion to the loss of 11b-HSD1 may be important regulators of
HPA axis function. In this regard, genetic dissection of 129 and
C57Bl⁄6J mice strains could identify important genes involved in
HPA regulation in health and disease. Inhibitors of 11ß-HSD1 are
in development for metabolic and age-related cognitive disorders
Strain-dependent HPA changes in HSD1
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analysis of relevant human genotypes may allow the determination
of sub-populations that may beneﬁt from treatment with such
agents without the unwanted side-effects of HPA axis dysregulation.
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